Literature DB >> 26796399

A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure.

Gary S Francis1, G Michael Felker2, W H Wilson Tang3.   

Abstract

Circulating natriuretic peptide measurements have been used extensively over the past 15 years to diagnose and monitor patients with heart failure. We are still learning how complex the dynamics of natriuretic peptides can be in the interpretation of test results in individual patients. Although natriuretic peptide measurements are widely used in practice, there are questions regarding why these peptides may not necessarily track with blood volume or invasive hemodynamic measurements in individual patients. Interpretation of natriuretic peptide measurements will depend on many factors, including special patient populations, obesity, renal function, the state of congestion or decongestion, and whether patients are receiving specific therapies. Natriuretic peptide measurements have clearly revolutionized clinical care for patients with heart failure, but further research should provide insights to help use these measurements to individualize patient care beyond the current guidelines.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BNP; NT-proBNP; biological markers; neprilysin

Mesh:

Substances:

Year:  2016        PMID: 26796399      PMCID: PMC4928678          DOI: 10.1016/j.jacc.2015.10.073

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  41 in total

1.  Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study.

Authors:  Sandeep R Das; Mark H Drazner; Daniel L Dries; Gloria L Vega; Harold G Stanek; Shuaib M Abdullah; Russell M Canham; Anne K Chung; David Leonard; Frank H Wians; James A de Lemos
Journal:  Circulation       Date:  2005-10-04       Impact factor: 29.690

2.  Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims.

Authors:  Robb D Kociol; John R Horton; Gregg C Fonarow; Eric M Reyes; Linda K Shaw; Christopher M O'Connor; G Michael Felker; Adrian F Hernandez
Journal:  Circ Heart Fail       Date:  2011-07-08       Impact factor: 8.790

3.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study.

Authors:  James L Januzzi; Carlos A Camargo; Saif Anwaruddin; Aaron L Baggish; Annabel A Chen; Daniel G Krauser; Roderick Tung; Renee Cameron; J Tobias Nagurney; Claudia U Chae; Donald M Lloyd-Jones; David F Brown; Stacy Foran-Melanson; Patrick M Sluss; Elizabeth Lee-Lewandrowski; Kent B Lewandrowski
Journal:  Am J Cardiol       Date:  2005-04-15       Impact factor: 2.778

Review 4.  Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.

Authors:  Alan H B Wu
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

5.  Molecular forms of atrial natriuretic factor in normal and failing human myocardium.

Authors:  R J Rodeheffer; M Naruse; J B Atkinson; K Naruse; J C Burnett; W H Merrill; W H Frist; H Demura; T Inagami
Journal:  Circulation       Date:  1993-08       Impact factor: 29.690

6.  N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.

Authors:  Paulo Bettencourt; Ana Azevedo; Joana Pimenta; Fernando Friões; Susana Ferreira; António Ferreira
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

7.  Impact of obesity on plasma natriuretic peptide levels.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

8.  Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.

Authors:  G Michael Felker; Tariq Ahmad; Kevin J Anstrom; Kirkwood F Adams; Lawton S Cooper; Justin A Ezekowitz; Mona Fiuzat; Nancy Houston-Miller; James L Januzzi; Eric S Leifer; Daniel B Mark; Patrice Desvigne-Nickens; Gayle Paynter; Ileana L Piña; David J Whellan; Christopher M O'Connor
Journal:  JACC Heart Fail       Date:  2014-09-03       Impact factor: 12.035

9.  Racial/Ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure.

Authors:  Selim R Krim; Rey P Vivo; Nassim R Krim; Feng Qian; Margueritte Cox; Hector Ventura; Adrian F Hernandez; Deepak L Bhatt; Gregg C Fonarow
Journal:  JACC Heart Fail       Date:  2013-08-05       Impact factor: 12.035

10.  Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide.

Authors:  Y Ogawa; K Nakao; M Mukoyama; K Hosoda; G Shirakami; H Arai; Y Saito; S Suga; M Jougasaki; H Imura
Journal:  Circ Res       Date:  1991-08       Impact factor: 17.367

View more
  20 in total

1.  Brain Natriuretic Peptide Is a Marker of Fluid Overload in Incident Hemodialysis Patients.

Authors:  Charles Chazot; Margaux Rozes; Cyril Vo-Van; Patrik Deleaval; Jean-Marc Hurot; Christie Lorriaux; Brice Mayor; Eric Zaoui; Guillaume Jean
Journal:  Cardiorenal Med       Date:  2017-04-29       Impact factor: 2.041

2.  Brain natriuretic peptide and shortness of breath in the emergency department.

Authors:  Yasbanoo Moayedi; Edward Etchells; Jeremy Kobulnik; Heather Ross
Journal:  CMAJ       Date:  2018-11-18       Impact factor: 8.262

Review 3.  Role of circulating factors in cardiac aging.

Authors:  Antonio Cannatà; Gabriella Marcon; Giovanni Cimmino; Luca Camparini; Giulio Ciucci; Gianfranco Sinagra; Francesco S Loffredo
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

4.  Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP.

Authors:  Yang Chen; Jacob J Schaefer; Seethalakshmi R Iyer; Gerald E Harders; Shuchong Pan; S Jeson Sangaralingham; Horng H Chen; Margaret M Redfield; John C Burnett
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-02-05       Impact factor: 3.619

Review 5.  Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment.

Authors:  Eva M Boorsma; Jozine M Ter Maaten; Kevin Damman; Wilfried Dinh; Finn Gustafsson; Steven Goldsmith; Daniel Burkhoff; Faiez Zannad; James E Udelson; Adriaan A Voors
Journal:  Nat Rev Cardiol       Date:  2020-05-15       Impact factor: 32.419

6.  Comparable prognostic impact of BNP levels among HFpEF, Borderline HFpEF and HFrEF: a report from the CHART-2 Study.

Authors:  Shintaro Kasahara; Yasuhiko Sakata; Kotaro Nochioka; Takeshi Yamauchi; Takeo Onose; Kanako Tsuji; Ruri Abe; Takuya Oikawa; Masayuki Sato; Hajime Aoyanagi; Masanobu Miura; Takashi Shiroto; Jun Takahashi; Satoshi Miyata; Hiroaki Shimokawa
Journal:  Heart Vessels       Date:  2018-03-22       Impact factor: 2.037

Review 7.  Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?

Authors:  Thanat Chaikijurajai; Hernan Rincon Choles; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2020-09-17

8.  Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study.

Authors:  Samuel S Gidding; Fida Bacha; Petter Bjornstad; Lorraine E Levitt Katz; Lynne L Levitsky; Jane Lynch; Jeanie B Tryggestad; Ruth S Weinstock; Laure El Ghormli; Joao A C Lima
Journal:  J Pediatr       Date:  2018-01       Impact factor: 4.406

9.  Increased extracellular water measured by bioimpedance and by increased serum levels of atrial natriuretic peptide in RA patients-signs of volume overload.

Authors:  Rainer H Straub; Boris Ehrenstein; Florian Günther; Luise Rauch; Nadezhda Trendafilova; Dario Boschiero; Joachim Grifka; Martin Fleck
Journal:  Clin Rheumatol       Date:  2016-04-26       Impact factor: 2.980

Review 10.  Novel Biological Therapies Targeting Heart Failure: Myocardial Rejuvenation.

Authors:  Amanda J Favreau-Lessard; Sergey Ryzhov; Douglas B Sawyer
Journal:  Heart Fail Clin       Date:  2016-05-10       Impact factor: 3.179

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.